Standard BioTools (LAB)
Market Price (5/10/2026): $1.02 | Market Cap: $396.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
Standard BioTools (LAB)
Market Price (5/10/2026): $1.02Market Cap: $396.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 20%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 15% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -108% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -113% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -91% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 34% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -105%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -110% Key risksLAB key risks include [1] persistent unprofitability and revenue contraction, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 20%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 15% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -108% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -113% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -91% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.7%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.6% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 34% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -105%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -110% |
| Key risksLAB key risks include [1] persistent unprofitability and revenue contraction, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Decline in Instrument Revenue Amid Capital-Constrained Markets. Standard BioTools experienced a significant 33% year-over-year decline in its instrument revenue, which fell to $4.5 million in the first quarter of 2026. This downturn is primarily attributed to "capital-constrained end markets" and "broader macro and funding constraints" affecting the company's operating environment. While overall revenue saw a modest 5% increase to $21.1 million, driven by strong consumables growth, the weakness in higher-value instrument sales likely contributed to investor apprehension regarding the company's core business health and future growth trajectory, leading to a loss of approximately 30% in its stock value since January 31, 2026.
2. Strategic Uncertainty Following SomaLogic Divestiture. Standard BioTools completed the sale of SomaLogic to Illumina on January 30, 2026, generating $363.2 million in cash proceeds and resulting in a total net income of $127.1 million from discontinued operations. Despite this substantial cash infusion, which increased the company's cash and investments to approximately $550 million, the market appears to be evaluating the company's standalone strategy for inorganic growth and capital deployment. The reiteration of full-year 2026 revenue guidance between $80 million and $85 million did not fully alleviate concerns, as investors may be cautious about the execution of a new growth strategy while core instrument sales face headwinds.
Show more
Stock Movement Drivers
Fundamental Drivers
The -27.1% change in LAB stock from 1/31/2026 to 5/9/2026 was primarily driven by a -26.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.40 | 1.02 | -27.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 86 | 86 | -0.1% |
| P/S Multiple | 6.2 | 4.6 | -26.0% |
| Shares Outstanding (Mil) | 383 | 388 | -1.4% |
| Cumulative Contribution | -27.1% |
Market Drivers
1/31/2026 to 5/9/2026| Return | Correlation | |
|---|---|---|
| LAB | -27.1% | |
| Market (SPY) | 3.6% | 43.5% |
| Sector (XLV) | -6.9% | 24.0% |
Fundamental Drivers
The -15.0% change in LAB stock from 10/31/2025 to 5/9/2026 was primarily driven by a -10.7% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.20 | 1.02 | -15.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 89 | 86 | -2.9% |
| P/S Multiple | 5.1 | 4.6 | -10.7% |
| Shares Outstanding (Mil) | 380 | 388 | -2.0% |
| Cumulative Contribution | -15.0% |
Market Drivers
10/31/2025 to 5/9/2026| Return | Correlation | |
|---|---|---|
| LAB | -15.0% | |
| Market (SPY) | 5.5% | 29.1% |
| Sector (XLV) | 0.3% | 17.7% |
Fundamental Drivers
The -8.1% change in LAB stock from 4/30/2025 to 5/9/2026 was primarily driven by a -24.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.11 | 1.02 | -8.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 115 | 86 | -24.9% |
| P/S Multiple | 3.6 | 4.6 | 26.8% |
| Shares Outstanding (Mil) | 375 | 388 | -3.5% |
| Cumulative Contribution | -8.1% |
Market Drivers
4/30/2025 to 5/9/2026| Return | Correlation | |
|---|---|---|
| LAB | -8.1% | |
| Market (SPY) | 30.4% | 39.1% |
| Sector (XLV) | 4.0% | 27.3% |
Fundamental Drivers
The -40.0% change in LAB stock from 4/30/2023 to 5/9/2026 was primarily driven by a -79.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.70 | 1.02 | -40.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 98 | 86 | -11.9% |
| P/S Multiple | 1.4 | 4.6 | 232.9% |
| Shares Outstanding (Mil) | 79 | 388 | -79.5% |
| Cumulative Contribution | -40.0% |
Market Drivers
4/30/2023 to 5/9/2026| Return | Correlation | |
|---|---|---|
| LAB | -40.0% | |
| Market (SPY) | 78.7% | 30.9% |
| Sector (XLV) | 13.0% | 21.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LAB Return | -35% | -70% | 89% | -21% | -27% | -22% | -83% |
| Peers Return | -2% | -47% | 19% | -32% | -10% | -8% | -65% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| LAB Win Rate | 42% | 25% | 50% | 33% | 50% | 60% | |
| Peers Win Rate | 53% | 37% | 53% | 37% | 47% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| LAB Max Drawdown | -40% | -76% | 0% | -36% | -47% | -31% | |
| Peers Max Drawdown | -11% | -60% | -35% | -45% | -47% | -23% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TXG, CTKB, QTRX, ILMN, QGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | LAB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.7% | -18.8% |
| % Gain to Breakeven | 50.8% | 23.1% |
| Time to Breakeven | 61 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -19.3% | -7.8% |
| % Gain to Breakeven | 23.9% | 8.5% |
| Time to Breakeven | 14 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.3% | -9.5% |
| % Gain to Breakeven | 47.8% | 10.5% |
| Time to Breakeven | 40 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.0% | -6.7% |
| % Gain to Breakeven | 42.9% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -67.2% | -33.7% |
| % Gain to Breakeven | 204.8% | 50.9% |
| Time to Breakeven | 45 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -57.3% | -3.7% |
| % Gain to Breakeven | 134.4% | 3.9% |
| Time to Breakeven | 558 days | 6 days |
In The Past
Standard BioTools's stock fell -33.7% during the 2025 US Tariff Shock. Such a loss loss requires a 50.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LAB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -33.7% | -18.8% |
| % Gain to Breakeven | 50.8% | 23.1% |
| Time to Breakeven | 61 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.3% | -9.5% |
| % Gain to Breakeven | 47.8% | 10.5% |
| Time to Breakeven | 40 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -30.0% | -6.7% |
| % Gain to Breakeven | 42.9% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -67.2% | -33.7% |
| % Gain to Breakeven | 204.8% | 50.9% |
| Time to Breakeven | 45 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -57.3% | -3.7% |
| % Gain to Breakeven | 134.4% | 3.9% |
| Time to Breakeven | 558 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -57.6% | -12.2% |
| % Gain to Breakeven | 135.6% | 13.9% |
| Time to Breakeven | 1130 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -40.2% | -17.9% |
| % Gain to Breakeven | 67.1% | 21.8% |
| Time to Breakeven | 717 days | 123 days |
In The Past
Standard BioTools's stock fell -33.7% during the 2025 US Tariff Shock. Such a loss loss requires a 50.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Standard BioTools (LAB)
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Standard BioTools:
They are like Illumina, but for advanced cell analysis and microfluidics instead of primarily DNA sequencing.
Think of them as a high-tech Thermo Fisher Scientific focused on innovative instruments and reagents for single-cell research and advanced biological imaging.
AI Analysis | Feedback
- Analytical Instruments: Systems such as Helios (CyTOF), Hyperion imaging systems, Biomark HD, and EP1 are used for sophisticated biological analysis in research and clinical laboratories.
- Preparatory Instruments: Tools like Juno systems and C1 systems are designed for sample preparation and single-cell analysis.
- Integrated Fluidic Circuits (IFCs): Microfluidic chips, including those for library preparation, genotyping, and dynamic arrays, are critical components enabling high-throughput experimentation.
- Assays and Reagents: Consumables such as Maxpar reagents (for immuno-oncology) and Advanta kits (for NGS library preparation and diagnostics) support various research and clinical applications.
- Software Solutions: Programs that accompany their instruments and assays facilitate operation, data acquisition, and analysis.
AI Analysis | Feedback
Major Customers of Standard BioTools (LAB)
Based on the provided company description, Standard BioTools Inc. does not list specific named major customers. Instead, the company sells its instruments, consumables, reagents, and software to a diverse range of organizations and institutions within the life sciences and research sectors. These customer categories include:
- Academic research institutions
- Translational research and medicine centers
- Cancer centers
- Clinical research laboratories
- Biopharmaceutical, biotechnology, and plant and animal research companies
- Contract research organizations (CROs)
While some of these categories represent "other companies" (e.g., biopharmaceutical, biotechnology, and CROs), the provided information does not specify individual company names or their respective stock symbols.
AI Analysis | Feedback
nullAI Analysis | Feedback
Michael Egholm, PhD – President and Chief Executive Officer
Dr. Michael Egholm leads Standard BioTools with over 25 years of leadership experience in developing and commercializing innovative technologies for biopharmaceuticals. Prior to joining Standard BioTools in April 2022, he served as the Chief Technology Officer of Danaher Life Sciences and was the founder and leader of the Danaher Corporation's venture fund. During his time at Danaher, he led the Pall Corporation's biopharmaceuticals business, where he was instrumental in redesigning its go-to-market structure, contributing to its multibillion-dollar revenue. Before Danaher, Dr. Egholm was the Chief Technology Officer at Roche's 454 Life Sciences Corporation, which was the first company to successfully commercialize next-generation sequencing. He spearheaded major initiatives, including the Neanderthal Sequencing project and the sequencing of the first individual human genome. Dr. Egholm is the named inventor of 40 U.S. patents and was the lead inventor of peptide nucleic acids (PNA) technology, for which he earned his PhD in organic chemistry from the University of Copenhagen.
Alex Kim – Chief Financial Officer
Alex Kim is the Chief Financial Officer of Standard BioTools, overseeing Finance, Accounting, IT, Legal, and Compliance functions. He became the interim Chief Financial Officer on September 1, 2024, following Jeffrey Black's resignation. Mr. Kim also served as the company's Chief Operating Officer and is a co-founder of Standard BioTools. He is recognized for his passion for improving healthcare and building businesses by accelerating innovative breakthroughs. As a core member of the executive team since the formation of Standard BioTools, he has played a significant role in developing its strategic plan.
Sean Mackay – Chief Business Officer
Sean Mackay brings a multidisciplinary background as an executive, investor, and investment banker, driving impact in the life sciences tools and therapeutics industries. Before joining Standard BioTools, Mr. Mackay was the co-founder and CEO of IsoPlexis, a life science tools company. He led IsoPlexis through its team building, product development, commercialization, initial public offering (IPO), and its eventual sale in 2023.
Betsy Jensen – Chief Human Resources Officer
Betsy Jensen leads the human resources function at Standard BioTools and has over 25 years of experience in transforming companies to achieve growth and profitability. Her career includes nearly eight years leading human resources and internal communications at several Danaher Corporation subsidiaries, such as Hach Company, Cepheid, Molecular Devices, and SCIEX. Most recently, she served as the Chief Human Resources Officer at Gibraltar Industries.
Anders Davas – Senior Vice President, Global Operations
Anders Davas serves as the Senior Vice President, Global Operations at Standard BioTools, a role he has held since April 2022, previously as Senior Vice President, Operational Excellence. Prior to joining Standard BioTools, Mr. Davas was the Vice President Global Manufacturing of Mölnlycke Health Care, a leading medical product and solution company. His responsibilities at Mölnlycke included the development and execution of manufacturing strategy, the design of a fit-for-purpose supply chain and manufacturing footprint, and the day-to-day management of large-scale manufacturing operations. Before Mölnlycke, he held the position of General Manager and Director at Pall Corporation in the UK.
AI Analysis | Feedback
Standard BioTools Inc. (LAB) faces several key risks inherent to its operations in the specialized life sciences tools market:
- Persistent Operating Losses and Uncertainty in Achieving Profitability: Despite efforts to optimize costs and a significant cash infusion from the sale of SomaLogic to Illumina, Standard BioTools continues to report substantial net losses from its continuing operations. For the full year 2025, the company reported a net loss of $74.9 million and an accumulated deficit of $1.3 billion as of December 31, 2025. The core business has experienced revenue declines, with Q3 2025 continuing operations revenue dropping 11% year-over-year. The company's financial precarity limits its ability to compete on price, scale, or marketing spend against larger, more profitable industry leaders. While management aims for positive adjusted EBITDA by the end of 2026, the underlying business currently struggles with core growth, creating significant uncertainty around achieving sustainable profitability.
- Intense Competition and Rapid Technological Obsolescence: Standard BioTools operates in a "highly dynamic life sciences tools market characterized by rapid technological convergence and intense competitive pressure." The company competes with numerous established and emerging players, including large-scale entities and specialized innovators in the high-value analytical systems and multi-omics markets. Its success depends on continuous innovation to keep pace with advancements in single-cell biology, genomics, and proteomics. Failure to anticipate or respond effectively to new technologies or competitor offerings could lead to its products becoming obsolete or losing market share, significantly impacting its business.
- Reliance on and Protection of Intellectual Property, and Sensitivity to Research Funding: The company's core competitive advantage is derived from its proprietary technological portfolio, including patented mass cytometry (CyTOF) technology and the SomaScan platform. It also holds license agreements with prominent institutions like the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. Any adverse events concerning its intellectual property portfolio, including challenges to its patents, the inability to protect its proprietary technologies, or issues with licensing agreements, could materially impact the company's financials. Furthermore, Standard BioTools' business model, which focuses on research tools, makes it vulnerable to reductions in research and development budgets or changes in funding priorities by its key customers, such as academic research institutions, biopharmaceutical companies, and government-funded programs like the NIH.
AI Analysis | Feedback
null
AI Analysis | Feedback
Standard BioTools Inc. (LAB) operates in several key addressable markets related to its instruments, consumables, reagents, and software for research and clinical laboratories. These markets include:
- Single-Cell Analysis: The global single-cell analysis market was valued at approximately USD 4.3 billion in 2024. It is projected to grow to USD 20 billion by 2034, with a compound annual growth rate (CAGR) of 16.7% from 2025 to 2034. North America holds a significant share, with the U.S. market reaching USD 1.8 billion in 2024. Another report estimates the global market at USD 4.94 billion in 2025, expected to reach USD 14.42 billion by 2032, growing at a CAGR of 16.5%. The market was also estimated at USD 4.64 billion in 2023, projected to reach USD 24.97 billion by 2033 at a CAGR of 18.33%.
- Mass Cytometry and Imaging Mass Cytometry: The mass cytometry market, which includes systems like Standard BioTools' Helios CyTOF and Hyperion imaging systems, was valued at approximately USD 500 million in 2025 and is projected to exhibit a CAGR of 15% from 2025 to 2033. The mass spectrometry imaging market, a related area, was valued at USD 2.65 billion in 2024 and is expected to grow to USD 4.07 billion in 2029 at a CAGR of 9%. North America was the largest region in the mass spectrometry imaging market in 2024.
- Next-Generation Sequencing (NGS) Library Preparation: The global next-generation sequencing library preparation market size was estimated at USD 1.75 billion in 2024 and is projected to reach USD 5.33 billion by 2033, with a CAGR of 13.3% from 2025 to 2033. North America held the largest share of 42.24% of the global market in 2024. Other estimates place the global market at USD 2.11 billion in 2025, reaching USD 7.17 billion by 2035 with a 13.5% CAGR, or USD 4.13 billion in 2024, growing to USD 14.3 billion by 2033 at a CAGR of 14.8%.
- Genotyping: The global genotyping market size was valued at USD 17.9 billion in 2023 and is expected to grow at a CAGR of 14.6% from 2024 to 2030, reaching USD 46.53 billion by 2030. Another report estimated the market size at USD 18.2 billion in 2022, growing at a CAGR of 15.9% between 2023 and 2032 to reach USD 78 billion. North America held a 41.4% revenue share in the genotyping market in 2022. The global market was also valued at USD 21.88 billion in 2024 and is projected to reach USD 63.29 billion by 2033, exhibiting a CAGR of 11.90% from 2025 to 2033.
- Real-Time PCR (qPCR): The global real-time PCR market size was estimated at USD 6.67 billion in 2025 and is expected to reach approximately USD 10.85 billion by 2035, expanding at a CAGR of 4.99% from 2026 to 2035. North America dominated this market with a 42% revenue share in 2025. Another source indicates the global real-time PCR (qPCR) systems market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2035, reflecting a CAGR of 8%.
- Microfluidics (Integrated Fluidic Circuits): The global microfluidics market size was valued at USD 34.91 billion in 2025 and is expected to reach USD 107.85 billion by 2035, growing at a CAGR of 11.94% from 2026 to 2035. North America held the largest revenue share of over 38.47% in this market in 2025. Other sources suggest the market was valued at USD 41.92 billion in 2025, projected to reach USD 105.13 billion by 2033, with a CAGR of 12.22% from 2026 to 2033, and another states the market was valued at USD 23.2 billion in 2023 and is estimated to reach USD 77.5 billion by 2033, growing at a CAGR of 13.7% from 2024 to 2033. Fluidigm Corporation, the former name of Standard BioTools, has been identified as a key company in the microfluidics market.
AI Analysis | Feedback
Standard BioTools Inc. (LAB) is expected to drive future revenue growth over the next two to three years through a combination of strategic acquisitions, increased adoption of its core life sciences tools, and deeper market penetration in its key application areas. Here are 3-5 expected drivers of future revenue growth: * Strategic Mergers & Acquisitions (M&A): Following the sale of SomaLogic to Illumina on January 30, 2026, Standard BioTools gained approximately $550 million in cash and investments. This substantial capital infusion provides the company with "real strategic flexibility" to "fuel inorganic growth strategy" and pursue "disciplined M&A" to build a diversified leader in life sciences. * Growth in Adoption and Utilization of Core Life Sciences Tools: The company's business is now laser-focused on its life sciences tools across three primary segments: Consumables, Instruments, and Services. Although the company has faced recent revenue declines in its continuing operations, with a 6% year-over-year decrease in full-year 2025 revenue from continuing operations, the strategic emphasis on operational efficiency and a streamlined business model is intended to drive the base business towards positive adjusted EBITDA and adjusted cash flow by the end of 2026. Increased adoption and utilization of their analytical and preparatory instruments, integrated fluidic circuits, and related assays and reagents would contribute to revenue growth. * Market Penetration and Expansion in Proteomics and Genomics: Standard BioTools specializes in proprietary mass cytometry and microfluidics technologies, providing solutions for proteomics and genomics research. The proteomics segment currently generates the majority of its revenue. Further market penetration and expanded use of their products, such as Helios, CyTOF, Hyperion imaging systems, and Maxpar reagents, within these critical research areas are anticipated to be revenue drivers.AI Analysis | Feedback
Standard BioTools (LAB) has undertaken several capital allocation decisions over the last three to five years, reflecting significant strategic shifts and financial restructuring.Share Repurchases
- Standard BioTools authorized a share repurchase program of up to $20 million of its common stock through December 31, 2023, announced in November 2022.
- In the first quarter of 2025, the company reported common stock repurchases amounting to approximately $11.05 million.
- For the full year 2025, share repurchases totaled approximately $40.49 million.
Share Issuance
- In January 2022, Fluidigm Corporation (now Standard BioTools) received $25 million in convertible unsecured term loans as part of a larger investment, which were subsequently converted into convertible preferred shares.
- In April 2022, stockholders approved the issuance of $250 million in convertible preferred shares to Casdin Capital and Viking Global Investors, including the conversion of the previously issued $25 million in term loans.
- Proceeds from Employee Stock Purchase Plan (ESPP) stock issuance were approximately $0.52 million in Q1 2025 and $0.92 million in 2024.
Inbound Investments
- In January 2022, the Board of Directors approved a $250 million strategic investment in Fluidigm Corporation (before its name change to Standard BioTools) by Casdin Capital, LLC, and Viking Global Investors LP.
- The $250 million capital infusion from Casdin Capital and Viking Global Investors was completed in April 2022, coinciding with the company's rebranding to Standard BioTools Inc.
Outbound Investments
- Standard BioTools completed the sale of SomaLogic to Illumina on January 30, 2026, generating $350 million in upfront cash.
Capital Expenditures
- Capital expenditures were reported as $13 million in 2021, $3.83 million in 2022, $2.83 million in 2023, and $8.36 million in 2024.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Standard BioTools Earnings Notes | 12/16/2025 | |
| With Standard BioTools Stock Surging, Have You Considered The Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to LAB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.11 |
| Mkt Cap | 1.7 |
| Rev LTM | 421 |
| Op Inc LTM | -61 |
| FCF LTM | 55 |
| FCF 3Y Avg | 16 |
| CFO LTM | 60 |
| CFO 3Y Avg | 30 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.9% |
| Rev Chg 3Y Avg | 4.0% |
| Rev Chg Q | 4.7% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 5.6% |
| Op Inc Chg 3Y Avg | 8.6% |
| Op Mgn LTM | -17.0% |
| Op Mgn 3Y Avg | -20.5% |
| QoQ Delta Op Mgn LTM | 2.8% |
| CFO/Rev LTM | 8.2% |
| CFO/Rev 3Y Avg | 5.9% |
| FCF/Rev LTM | 6.4% |
| FCF/Rev 3Y Avg | 2.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.7 |
| P/S | 3.8 |
| P/Op Inc | -3.2 |
| P/EBIT | 6.3 |
| P/E | 1.9 |
| P/CFO | 4.7 |
| Total Yield | 1.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.4% |
| D/E | 0.1 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.2% |
| 3M Rtn | -8.0% |
| 6M Rtn | -5.0% |
| 12M Rtn | 26.5% |
| 3Y Rtn | -45.7% |
| 1M Excs Rtn | -11.6% |
| 3M Excs Rtn | -14.7% |
| 6M Excs Rtn | -6.6% |
| 12M Excs Rtn | -19.6% |
| 3Y Excs Rtn | -126.9% |
Price Behavior
| Market Price | $1.02 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 02/10/2011 | |
| Distance from 52W High | -39.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.95 | $1.24 |
| DMA Trend | down | down |
| Distance from DMA | 6.9% | -17.7% |
| 3M | 1YR | |
| Volatility | 48.6% | 63.5% |
| Downside Capture | 1.00 | 0.86 |
| Upside Capture | 60.24 | 112.71 |
| Correlation (SPY) | 36.1% | 36.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.47 | 1.00 | 1.34 | 1.35 | 2.03 | 1.51 |
| Up Beta | 0.35 | 0.33 | 0.34 | 1.23 | 2.67 | 1.61 |
| Down Beta | 2.13 | 1.33 | 1.47 | 1.75 | 2.07 | 1.37 |
| Up Capture | 18% | 36% | 61% | 83% | 142% | 178% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 9 | 17 | 24 | 51 | 107 | 340 |
| Down Capture | 387% | 201% | 243% | 152% | 163% | 111% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 13 | 26 | 37 | 66 | 124 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LAB | |
|---|---|---|---|---|
| LAB | 7.1% | 63.8% | 0.35 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 25.2% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 37.3% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 0.5% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -5.4% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 26.3% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 25.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LAB | |
|---|---|---|---|---|
| LAB | -26.9% | 78.0% | -0.06 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 21.4% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 32.4% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 3.8% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 3.4% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 24.5% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LAB | |
|---|---|---|---|---|
| LAB | -20.0% | 82.8% | 0.12 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 22.7% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 29.1% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 7.3% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 9.1% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 21.1% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | -1.1% | ||
| 1/30/2026 | -0.7% | -12.1% | -22.0% |
| 11/4/2025 | -4.2% | 0.0% | 20.2% |
| 8/11/2025 | 2.3% | -0.8% | 0.0% |
| 5/6/2025 | -3.8% | 7.5% | -6.2% |
| 1/13/2025 | 26.4% | 8.6% | -19.9% |
| 10/30/2024 | 4.3% | 20.2% | -2.1% |
| 7/31/2024 | -36.6% | -29.5% | -7.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 14 | 11 |
| # Negative | 14 | 8 | 11 |
| Median Positive | 11.2% | 10.8% | 18.1% |
| Median Negative | -4.5% | -9.6% | -9.5% |
| Max Positive | 26.4% | 55.0% | 38.6% |
| Max Negative | -36.6% | -29.6% | -36.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/15/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/11/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 80.00 Mil | 82.50 Mil | 85.00 Mil | 0 | Affirmed | Guidance: 82.50 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 80.00 Mil | 82.50 Mil | 85.00 Mil | ||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Casdin, Partners Master Fund, LP | See footnote | Buy | 12042025 | 1.45 | 150,000 | 217,020 | 104,314,280 | Form | |
| 2 | Casdin, Partners Master Fund, LP | See footnote | Buy | 12042025 | 1.44 | 75,000 | 108,037 | 103,643,975 | Form | |
| 3 | Casdin, Partners Master Fund, LP | See footnote | Buy | 12042025 | 1.42 | 125,000 | 177,512 | 102,069,688 | Form | |
| 4 | Casdin, Partners Master Fund, LP | See footnote | Buy | 11262025 | 1.30 | 7,550,000 | 9,838,405 | 93,497,425 | Form | |
| 5 | Casdin, Partners Master Fund, LP | See footnote | Buy | 11262025 | 1.43 | 150,000 | 214,875 | 91,966,500 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.